Shots: Two doctors called for interchangeability requirements for biologics to be waived for insulin products under the Biologics Price Competition and Innovation Act (BPCIA) of 2009 The FDA guidance is a reminder that the rules of BPCIA should be carefully reinterpreted in order to maximize benefit, affordability, and access to insulin for all patients with […]Read More
